Dextrin-colistin conjugates as a model bioresponsive treatment for multidrug resistant bacterial infections

Molecular Pharmaceutics

Volumn 11, Issue 12, 2014, Pages 4437-4447

  Ferguson, Elaine L ^a   Azzopardi, Ernest ^a,b   Roberts, Jessica L ^a,c   Walsh, Timothy R ^a   Thomas, David W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c BANGOR UNIVERSITY   (United Kingdom)

Author keywords

Bioresponsive; Gram negative bacteria; Infection; Nanomedicines; Polymer therapeutics; Pumpt

Indexed keywords

AMYLASE; COLISTIN; DEXTRIN; ANTIINFECTIVE AGENT; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIMICROBIAL ACTIVITY; ARTICLE; BOLUS INJECTION; CELL VIABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG STABILITY; ENZYME DEGRADATION; GRAM NEGATIVE INFECTION; HEMOLYSIS; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INFECTION RESISTANCE; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MOUSE; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA HALF LIFE; PRIORITY JOURNAL; RAW 264.7 CELL LINE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ANIMAL; CHEMISTRY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; NANOMEDICINE; PROCEDURES; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; DEXTRINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; NANOMEDICINE; POLYMERS; RATS;

EID: 84928909372     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500584u     Document Type: Article

References (36)

1. Boucher, H. W.; Talbot, G. H.; Bradley, J. S.; Edwards, J. E.; Gilbert, D.; Rice, L. B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48, 1-12.
2. Falagas, M. E.; Michalopoulos, A. Polymyxins: old antibiotics are back. Lancet 2006, 367, 633-634.
3. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6, 688-701.
4. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discovery 2003, 2, 347-360.
5. Hardwicke, J.; Ferguson, E. L.; Moseley, R.; Stephens, P.; Thomas, D.; Duncan, R. Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair. J. Controlled Release 2008, 130, 275-283.
6. Hardwicke, J.; Moseley, R.; Stephens, P.; Harding, K.; Duncan, R.; Thomas, D. W. Bioresponsive dextrin-rhEGF conjugates: in vitro evaluation in models relevant to its proposed use as a treatment for chronic wounds. Mol. Pharmaceutics 2010, 7, 699-707.
7. Hardwicke, J.; Song, B.; Moseley, R.; Thomas, D. W. Investigation of the potential of polymer therapeutics in corneal re-epithelialisation. Br. J. Ophthalmol. 2010, 94, 1566-1570.
8. Hardwicke, J. T.; Hart, J.; Bell, A.; Duncan, R.; Thomas, D. W.; Moseley, R. The effect of dextrin-rhEGF on the healing of full-thickness, excisional wounds in the (db/db) diabetic mouse. J. Controlled Release 2011, 152, 411-417.
9. Duncan, R. Polymer therapeutics: Top 10 selling pharmaceuticals - What next? J. Controlled Release 2014, 190, 371-380.
10. Sanchis, J.; Canal, F.; Lucas, R.; Vicent, M. J. Polymer-drug conjugates for novel molecular targets. Nanomedicine 2010, 5, 915-935.
11. Azzopardi, E. A.; Ferguson, E. L.; Thomas, D. W. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. J. Antimicrob. Chemother. 2013, 68, 257-274.
12. Duncan, R.; Gilbert, H. R. P.; Carbajo, R. J.; Vicent, M. J. Polymer masked-unmasked protein therapy (PUMPT) 1. Bioresponsive dextrintrypsin and -MSH conjugates designed for α-amylase activation. Biomacromolecules 2008, 9, 1146-1154.
13. Azzopardi, E. A.; Ferguson, E. L.; Thomas, D. W. Colistin past and future: a bibliographic analysis. J. Crit. Care 2013, 28, 219.e13-19.
14. Hreczuk-Hirst, D.; Chicco, D.; German, L.; Duncan, R. Dextrins as potential carriers for drug targeting: tailored rates of dextrin degradation by introduction of pendant groups. Int. J. Pharm. 2001, 230, 57-66.
15. Hreczuk-Hirst, D.; German, L.; Duncan, R. Dextrins as Carriers for Drug Targeting: Reproducible Succinoylation as a Means to Introduce Pendant Groups. J. Bioact. Compat. Polym. 2001, 16, 353-365.
16. Khan, S.; Tondervik, A.; Sletta, H.; Klinkenberg, G.; Emanuel, C.; Onsoyen, E.; Myrvold, R.; Howe, R. A.; Walsh, T. R.; Hill, K. E.; Thomas, D. W. Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics. Antimicrob. Agents Chemother. 2012, 56, 5134-5141.
17. Jorgensen, J. H.; Turnidge, J. D.; Washington, J. A. Antibacterial susceptibility tests: dilution and disk diffusion methods, In Manual of Clinical Microbiology, 7th ed.; Murray, P. R., Baron, E. J., Pfaller, M. A., Jorgensen, J. H., Yolken, R. H., Eds.; ASM Press: Washington, DC, 1999; pp 1526-1543.
18. Ferguson, E. L.; Duncan, R. Dextrin-phospholipase A2: synthesis and evaluation as a novel bioresponsive anticancer conjugate. Biomacromolecules 2009, 10, 1358-1364.
19. Couet, W.; Gregoire, N.; Gobin, P.; Saulnier, P. J.; Frasca, D.; Marchand, S.; Mimoz, O. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin. Pharmacol. Ther. 2011, 89, 875-879.
20. Skude, G.; Kollberg, H. Serum isoamylases in cystic fibrosis. Acta Paediatr. Scand. 1976, 65, 145-149.
21. Newton, B. A. The properties and mode of action of the polymyxins. Bacteriol. Rev. 1956, 20, 14-27.
22. Biswas, S.; Brunel, J. M.; Dubus, J. C.; Reynaud-Gaubert, M.; Rolain, J. M. Colistin: an update on the antibiotic of the 21st century. Expert Rev. Anti Infect. Ther. 2012, 10, 917-934.
23. Berg, J. R.; Spilker, C. M.; Lewis, S. A. Effects of polymyxin B on mammalian urinary bladder. J. Membr. Biol. 1996, 154, 119-130.
24. Lewis, J. R.; Lewis, S. A. Colistin interactions with the mammalian urothelium. Am. J. Physiol.: Cell Physiol. 2004, 286, C913-922.
25. Falagas, M. E.; Kasiakou, S. K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care 2006, 10, R27.
26. Ryan, M. J.; Johnson, G.; Kirk, J.; Fuerstenberg, S. M.; Zager, R. A.; Torok-Storb, B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int. 1994, 45, 48-57.
27. Vaara, M.; Fox, J.; Loidl, G.; Siikanen, O.; Apajalahti, J.; Hansen, F.; Frimodt-Moller, N.; Nagai, J.; Takano, M.; Vaara, T. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob. Agents Chemother. 2008, 52, 3229-3236.
28. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement M100-S21; CLSI: Wayne, PA, 2011; Vol. 31.
29. Forest Laboratories UK Limited. Colomycin [package insert], Dartford, U. K., 2012.
30. Li, J.; Coulthard, K.; Milne, R.; Nation, R. L.; Conway, S.; Peckham, D.; Etherington, C.; Turnidge, J. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 2003, 52, 987-992.
31. Li, J.; Milne, R. W.; Nation, R. L.; Turnidge, J. D.; Coulthard, K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob. Agents Chemother. 2003, 47, 1364-1370.
32. Li, J.; Milne, R. W.; Nation, R. L.; Turnidge, J. D.; Smeaton, T. C.; Coulthard, K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob. Agents Chemother. 2003, 47, 1766-1770.
33. Li, J.; Milne, R. W.; Nation, R. L.; Turnidge, J. D.; Smeaton, T. C.; Coulthard, K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J. Antimicrob. Chemother. 2004, 53, 837-840.
34. Wannachaiyasit, S.; Chanvorachote, P.; Nimmannit, U. A novel anti-HIV dextrin-zidovudine conjugate improving the pharmacokinetics of zidovudine in rats. AAPS PharmSciTech 2008, 9, 840-850.
35. Mcgeachin, R. L.; Gleason, J. R.; Adams, M. R. Amylase distribution in extrapancreatic, extrasalivary tissues. Arch. Biochem. Biophys. 1958, 75, 403-411.
36. Liu, Q.; Djuricin, G.; Rossi, H.; Bewsey, K.; Nathan, C.; Gattuso, P.; Weinstein, R. A.; Prinz, R. A. The effect of lexipafant on bacterial translocation in acute necrotizing pancreatitis in rats. Am. Surg. 1999, 65, 611-617.